Delayed hemolytic transfusion reaction in children with sickle cell disease

Haematologica

Volumn 96, Issue 6, 2011, Pages 801-807

  de Montalembert, Mariane ^a,b   Dumont, Marie Dominique ^a   Heilbronner, Claire ^a,c   Brousse, Valentine ^a,c   Charrara, Oussama ^d   Pellegrino, Béatrice ^e   Piguet, Christophe ^f   Soussan, Valérie ^g   Noizat Pirenne, France ^h  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Centre de Référence de la Drépanocytose   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^f Mère Enfant Hospital   (France)

^g HÔPITAL AMBROISE PARÉ   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

Allo immunization; Intravenous immunoglobulin; Rituximab; Sickle cell disease; Transfusion

Indexed keywords

ALLOANTIBODY; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; HEMOGLOBIN; HYDROXYUREA; IMMUNOGLOBULIN; MACROLIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RIFAMPICIN;

ACUTE CHEST SYNDROME; ADOLESCENT; ANTIBODY PRODUCTION; ARTICLE; ARTIFICIAL VENTILATION; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BONE PAIN; CHILD; CLINICAL ARTICLE; DELAYED HEMOLYTIC TRANSFUSION REACTION; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FRANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; MALE; MEDICAL RECORD REVIEW; OSTEOMYELITIS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RETICULOCYTE COUNT; RETICULOCYTOPENIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA;

EID: 79958072849     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.038307     Document Type: Article

References (25)

1. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol. 2001;38(1 Suppl 1):5-13.
2. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):16171-1621.
3. Noizat-Pirenne F, Lee K, Le Pennec PY, Simon P, Kazup P, Bachir D, et al. Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety. Blood. 2002;100(12): 4223-4231.
4. Noizat-Pirenne F. Immunohematologic characteristics in the Afro-caribbean population. Consequences for transfusion safety. Transfus Clin Biol. 2003;10(3):185-191.
5. Scheunemann LP, Ataga KI. Delayed haemolytic transfusion reaction in sickle cell disease. Am J Med Sci. 2010;339(3):266-269.
6. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed haemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003:111(6 Pt 1):e661-e665.
7. Petz LD, Calhoun L, Shulman IA, Johnson C, Herron RM. The sickle cell hemolytic transfusion reaction syndrome. Transfusion.1997;37(4):382-392.
8. Cullis JO, Win N, Dudley JM, Kaye T. Posttransfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang. 1995; 6(4)9:355-35
9. Win N, Doughty H, Telfer P, Wild BJ, Pearson TC. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion. 2001;41(3):323-32
10. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed haemolytic transfusions reactions in patients with sickle cell disease. Arch Intern Med.1988;148(11):2485-248
11. Tournamille C, Meunier-Costes N, Costes B, Martret J, Barrault A, Gauthier P, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of allommunization. Transfusion. 2010; 50(1):13-1.
12. Chadebech P, Habibi A, Nzouakou R, Bachir D, Meunier-Costes N, Bonin P, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9):1785-17.
13. Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron JC, et al. Rituximab for prevention of delayed haemolytic transfusion reaction in sickle cell disease. Haematologica. 2007;92(12):e132-e135.
14. Elenga N, Mialou V, Kebaili K, Galambrun C, Bertrand Y, Pondarre C. Severe neurologic complication after delayed haemolytic transfusion reaction in 2 children with sickle cell anemia. J Pediatr Hematol Oncol. 2008;30(12):928-90.
15. Bachmeyer C, Maury J, Parrot A, Bachir D, Stankovic K, Girot R, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol. 2010;85(1):91-9.
16. Zimring JC, Spitalnik SL. To RBC or not to RBC: the role of suicidal death in hemolytic transfusion reactions. Transfusion. 2009; 49(9):1776-1778.
17. Neidlinger NA, Larkin SK, Bhagat A, Victorino GP, Kuypers FA. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem. 2006;281(2):775-781.
18. Hod EA, Sokol SA, Zimring JC, Spitalnik SL. Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis. Int J Clin Exp Pathol. 2009;2(1):71-82.
19. Platt OS. Sickle cell disease as an inflammatory disease. J Clin Invest. 2000;106(3):337-338.
20. Ni Choileain N, Redmond HP. Cell response to surgery. Arch Surg. 2006;141(11):1132-1140.
21. Win N, Sinha S, Lee E, Mills W. Treatment with intravenous immunoglobuline and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev. 2010;24(1):64-67.
22. Couillard S, Benkerrou M, Girot R, Brousse V, Ferster A, Bader-Meunier B. Steroid treatment in children with sickle cell disease. Haematologica. 2007;92(3):425-426.
23. Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev. 2008;22(2):103-116.
24. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIG? Blood. 2007;109(1): 155-158.
25. Kurosawa S, Kato M. 2008. Anesthetics, immune cells, and immune responses. J Anesth. 2008;22(3):263-277.